
Broad pipeline targeting early to late-stage cancer treatment



^{1.} Wholly-owned by Nykode. Potentially registrational. Roche supplies atezolizumab; 2. Wholly-owned by Nykode. Merck (MSD) supplies pembrolizumab; 3. Wholly-owned Nykode. 4. Collaboration with Regeneron; 5. Genentech has an exclusive license to VB10.NEO.